XPro 1595

Drug Profile

XPro 1595

Alternative Names: XPro1595

Latest Information Update: 26 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emory University; Xencor
  • Developer Emory University; FPRT Bio
  • Class Recombinant proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 03 Dec 2012 XPro 1595 is licensed to FPRT Bio
  • 03 Dec 2012 Preclinical trials in Neurodegenerative disorders in USA (SC)
  • 03 Dec 2012 Preclinical trials in Parkinson's disease in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top